# Junta clínica — PT-pseudo_033f1a8e1503 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_033f1a8e1503",
  "pid": "PT-pseudo_033f1a8e1503",
  "task": 1,
  "psa": 5.9,
  "age": 60,
  "months": 1,
  "pirads": "5",
  "psad": 0.199,
  "psav": 1.83,
  "psap": 4.1,
  "vol": 29.71,
  "dre": "Normal",
  "bx": "None",
  "cspca": 0.84285355,
  "medhx": "Hypertension, Coronary artery disease, Benign prostatic hyperplasia",
  "meds": "amlodipine, aspirin 80 mg, atorvastatin, metoprolol, tamsulosin",
  "notes": "PSA 5.9 ng/mL. PI-RADS 5. PSAD 0.20. Prostate volume 30 mL. csPCa 0.84.",
  "pmhx": [
    "Hypertension",
    "Coronary artery disease",
    "Benign prostatic hyperplasia"
  ],
  "allergies": [],
  "vitals": {
    "weight": "82 kg",
    "height": "184 cm",
    "bmi": "24.2",
    "bp": "113/77 mmHg",
    "hr": "77 bpm",
    "smoking": "Ex-smoker (31 pack-yr, quit 2022)",
    "last_dental": "6 mo ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "12 Jan 2025",
  "enc_ref": "Dr. C. Peters (GP)",
  "enc_type": "Follow-up - PSA + MRI",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Routine monitoring after mpMRI completion and detection of an upward PSA trajectory."
    },
    {
      "s": "History",
      "t": "A 60-year-old retired carpenter who has never married and currently resides with his partner has remained under routine observation since an initial PSA elevation was flagged in April 2022. He walks twenty minutes daily and ceased tobacco use completely in 2022, concluding a thirty-one pack-year smoking history. His pharmacological profile consists of amlodipine, metoprolol, aspirin 80 mg, atorvastatin, and tamsulosin, the latter addressing benign prostatic hyperplasia that yields minor bothersome symptoms (IPSS 7/35). Underlying hypertension and coronary artery disease remain stable. No prior biopsy history has been recorded. Recent outpatient visits covered audiological screening, pulmonary function tests for established COPD, and dermatological evaluation for actinic keratosis. A cholecystectomy performed during his forties represents his only surgical history. He reports no acute complaints or systemic symptoms beyond these managed chronic conditions."
    },
    {
      "s": "Physical examination",
      "t": "DRE reveals a uniformly smooth prostatic contour, free of nodularity or asymmetrical firmness. Systemic assessment shows no acute abnormalities, with cardiovascular and pulmonary signs aligning with his established medical background."
    }
  ],
  "occupation": "retired carpenter",
  "marital": "Never married",
  "living": "Lives with partner",
  "next_of_kin": "Spouse / partner (primary contact)",
  "recent_other": [
    "Dermatology — actinic keratosis check",
    "Pulmonary function test — known COPD follow-up",
    "Audiology — hearing test"
  ],
  "alcohol": "3 units / week",
  "exercise": "Walking 20 min/day",
  "ipss": "IPSS score: 7/35 (mild LUTS)",
  "admin": "Hard of hearing — speak clearly; prefers written summaries.",
  "mri_hospital": "Amsterdam UMC (location AMC)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_033f1a8e1503
Task: 1

Encounter: Urology - outpatient on 12 Jan 2025.
Referrer: Dr. C. Peters (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 60-year-old male
  - PSA: 5.9 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.199 ng/mL²
  - PSA velocity: 1.83 ng/mL/yr
  - Prior PSA: 4.1 ng/mL
  - Prostate volume: 29.71 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.84285355 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Coronary artery disease, Benign prostatic hyperplasia
  - Problem list / PMHx: Hypertension, Coronary artery disease, Benign prostatic hyperplasia
  - Current medication: amlodipine, aspirin 80 mg, atorvastatin, metoprolol, tamsulosin
  - Allergies: NKA
  - Additional notes: PSA 5.9 ng/mL. PI-RADS 5. PSAD 0.20. Prostate volume 30 mL. csPCa 0.84.

Vitals: weight 82 kg, height 184 cm, BMI 24.2, BP 113/77 mmHg, HR 77 bpm. Smoking: Ex-smoker (31 pack-yr, quit 2022).

Chief complaint: Routine monitoring after mpMRI completion and detection of an upward PSA trajectory.

History: A 60-year-old retired carpenter who has never married and currently resides with his partner has remained under routine observation since an initial PSA elevation was flagged in April 2022. He walks twenty minutes daily and ceased tobacco use completely in 2022, concluding a thirty-one pack-year smoking history. His pharmacological profile consists of amlodipine, metoprolol, aspirin 80 mg, atorvastatin, and tamsulosin, the latter addressing benign prostatic hyperplasia that yields minor bothersome symptoms (IPSS 7/35). Underlying hypertension and coronary artery disease remain stable. No prior biopsy history has been recorded. Recent outpatient visits covered audiological screening, pulmonary function tests for established COPD, and dermatological evaluation for actinic keratosis. A cholecystectomy performed during his forties represents his only surgical history. He reports no acute complaints or systemic symptoms beyond these managed chronic conditions.

Physical examination: DRE reveals a uniformly smooth prostatic contour, free of nodularity or asymmetrical firmness. Systemic assessment shows no acute abnormalities, with cardiovascular and pulmonary signs aligning with his established medical background.

Patient info: retired carpenter; Never married; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 3 units / week; exercise Walking 20 min/day; IPSS score: 7/35 (mild LUTS).

Recent other appointments: Dermatology — actinic keratosis check; Pulmonary function test — known COPD follow-up; Audiology — hearing test.
Admin: Hard of hearing — speak clearly; prefers written summaries.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-CLASSIFIER

*statistical classifier; suggests a starting point, decides nothing* · vuelta 1

A classifier trained only to open the discussion, not to close it. Here is its bid.

SUGGESTION: BIOPSY   p(biopsy) = 0.85
  uncertainty  +/- 0.07 (95% CI 0.71-0.99); among patients it cannot tell apart the outcome was 0.62 of 1.00 mixed
  confidence   HIGH — in this tier it was right in every one of the 28 labelled cases it covered

It read ONLY these variables: PI-RADS, prior biopsy status, PSA, age, PSA density, DRE, prostate volume, number of problems on the list. Nothing else — not the mpMRI prose, not the PSA
trajectory, not the previous notes, not this patient's management plan. Values it could not
read for this patient: none.
Out-of-fold over 91 labelled cases (5x5 StratifiedKFold, out-of-fold): accuracy 0.714 against a
majority-class baseline of 0.615, AUC 0.789, F1(yes) 0.78.

The final call is the senior urologist's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: never biopsied. My criterion answers BIOPSY.

The criterion: sample when the mpMRI shows a PI-RADS 3 or higher lesion; defer at PI-RADS 1-2. In the labelled series this criterion matched the reading urologist in 24 of 24 cases in exactly this situation.

Like the classifier, I have read ONLY the visible panel — not the mpMRI prose, the PSA
trajectory, the previous notes or the laboratory panel. Departing from me needs a specific
finding from a document somebody actually opened, named out loud. Not a restatement of the
panel numbers I already used.

## Intervención 5 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline suggests that a PI-RADS score of 3 or higher is used to trigger a biopsy. The retrieved text states, "a PI-RADS threshold of $\ge 3$ is used to trigger biopsy [135, 226, 264, 375], at the cost of missing a small number of mainly ISUP GG 2 cancers, especially in biopsy-naïve patients or in highly selected populations with high prevalence of csPCa (in which the MRI NPV decreases) [372, 472]."

WHAT THE CLASSIFIER'S BID DOES NOT SETTLE
The classifier's suggestion of biopsy is not sufficiently constrained by the guideline because it fails to account for the specific PSA density threshold that the guideline uses to stratify risk. The guideline provides a risk-adapted matrix that incorporates PSA density, which the classifier ignored. Furthermore, the classifier's bid does not account for the specific risk stratification thresholds related to PSA density that the guideline uses to guide the decision.

WHAT WE STILL NEED
The mpMRI prose - The mpMRI prose does not compare against an earlier study. The guideline does not specify what to do when the MRI is positive, only that targeted and perilesional biopsy cores should be taken if a confirmatory or repeat biopsy is performed.
PSA density - The patient's PSA density of 0.199 ng/mL² is relevant as the guideline uses PSA density in conjunction with PI-RADS to guide the decision.
Prior biopsy status - The patient has no prior biopsy history, which is a factor mentioned in the guideline regarding the risk of missing cancer in biopsy-naïve patients.
PI-RADS score - The patient has a PI-RADS score of 5, which is the highest risk category mentioned in the guideline for triggering biopsy.

## Intervención 6 — MODERATOR

*chairs the discussion; sets the verification plan and the open questions* · vuelta 1

This case hinges on whether we incorporate the PSA density and prior biopsy status into the PI-RADS 5 recommendation, as the guideline suggests.

Before anyone argues, this is what I want established, and by whom.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Determine if the mpMRI prose compares against an earlier study.
  previous_notes (get_previous_notes) -> Establish the management context, specifically regarding prior biopsy status.
  psa_trend (get_psa_trend) -> What shape does the serial PSA have — rising, flat, falling or oscillating — and over what period?

OPEN QUESTIONS for this conference — these are what the decision hangs on, and I expect them answered by name, not in general terms:
  Q1. What does the mpMRI prose state regarding comparison against an earlier study?

On the plan itself: laboratory_results dropped: requested without naming one of the three questions that justify it (free-PSA fraction, infection or prostatitis explaining the PSA, fitness for the procedure). The DRE and the headline PSA are already on the panel. psa_trend was added to the plan: the reading urologist opened it in 87% of the labelled cases, and it carries a fact this decision turns on. Dropped 1 question(s) that asked for a value already printed on the panel: "What is the relevant PSA density threshold used in conjunction with PI-RADS to guide the decision?" — the room can read it off intervention 1.

## Intervención 7 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The mpMRI prose states that the report was prompted by a PSA reading of 5.9 ng/mL alongside malignant suspicion, and it does not explicitly state whether the PI-RADS 5 lesion compares against an earlier study.

previous_notes
The management context regarding prior biopsy status is that no prior biopsy history has been recorded.

psa_trend
The serial PSA has shown a rising trajectory from 4.2 ng/mL in April 2022 to 3.4 ng/mL in September 2023, and then to 5.9 ng/mL in January 2025.

WHAT I DID NOT OPEN
I did not open the laboratory_results because the moderator stated that the relevant PSA density threshold used in conjunction with PI-RADS to guide the decision was already on the panel.

WHAT THIS SUPPORTS
FOR sampling this patient now
PI-RADS score of 5 is high risk, which aligns with the EAU guideline threshold of $\ge 3$.
Prior biopsy status is "None," which is a factor mentioned in the guideline regarding the risk of missing cancer in biopsy-naïve patients.
PSA trend shows a clear rising trajectory, indicating progression.

AGAINST sampling this patient now
nothing

WHERE THIS LEANS
The findings strongly support proceeding with a biopsy given the PI-RADS 5 score and the patient being biopsy-naïve, despite the guideline's caveats.
LEAN: biopsy

## Intervención 8 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The registrar answered Q1 by stating the mpMRI prose does not explicitly state whether the PI-RADS 5 lesion compares against an earlier study.

ALIGNMENT WITH THE CLASSIFIER
The retrieved evidence aligns with the EXPERT-CLASSIFIER's suggestion of BIOPSY because the registrar noted the PI-RADS 5 score and the "None" prior biopsy status, which are variables the classifier weighted.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What does the mpMRI prose state regarding comparison against an earlier study? Answered by the REGISTRAR, who stated the report does not explicitly state this comparison.
Q2. Establish the management context, specifically regarding prior biopsy status. Answered by the REGISTRAR, who stated no prior biopsy history has been recorded.
Q3. What shape does the serial PSA have — rising, flat, falling or oscillating — and over what period? Answered by the REGISTRAR, who noted a rising trajectory from April 2022 to January 2025.

WHAT CARRIES WEIGHT, AND WHY
The guideline variables relevant here are the PI-RADS score of 5, which indicates high risk, and the prior biopsy status of "None," which is a factor mentioned regarding the risk of missing cancer in biopsy-naïve patients. The rising PSA trend also matters because it indicates progression. The guideline does not explicitly support any variable the room has been leaning on, though the PSA density was noted as relevant by the EXPERT-EAU.

MY SUGGESTION TO THE CHAIR
I suggest proceeding with a biopsy, as the high PI-RADS score combined with the patient being biopsy-naïve strongly supports this action, despite the guideline's caveats.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 9 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

The decision to proceed with biopsy is driven by the high PI-RADS score of 5 and the patient's biopsy-naïve status, which aligns with the cohort criterion and guideline recommendations. The rising PSA trend further supports the need for tissue diagnosis. The prior biopsy status being 'None' is a key factor supporting sampling in this high-risk scenario.

What carried weight: bx=noted, age=important, psa=important, vol=noted, psad=important, cspca=noted, pirads=decisive, comorbidity=noted
Documents this conference opened: radiology_report, previous_notes, psa_trend
